Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
In the United States, the incidence of biliary tract cancer and gallbladder cancer has been
estimated to be 6,000-8,000 patients per year. Currently, there is no standard therapy for
these tumors once the disease has spread and is inoperable. Recent small studies with
gemcitabine have shown a positive response rate. The investigators plan to test the
combination of gemcitabine with cisplatin for biliary tract and gallbladder cancers.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Eli Lilly and Company Massachusetts General Hospital